Nuvilex today announced favorable results of a completed Phase 2 clinical trial carried out in Europe to combat Pancreatic Cancer. The Company announced last week that it had acquired the treatment technology which involves the use of encapsulated cells.

The trial demonstrated both efficacy and an improvement in quality of life, due in large part to the reduction in toxicity levels from lower dose chemotherapy. Highlights of the trial, which were compared to Eli Lilly’s (NYSE: LLY) Gemzar®, the current gold standard chemotherapy, include:

• Results demonstrated a 100% increase in patients’ median survival rate;
• The 1-year survival rate was twice that observed with the current gold standard;
• Chemotherapy dose needed was only one-third the normal amount;
• Improved quality of life was noted in more than half of the patients.

In the US alone, 37,000 people die every year from Pancreatic Cancer. It is widely regarded as the single most aggressive form of cancer. Nuvilex is aggressively pursuing the next phase of development of this treatment technology.

NVLX closed today’s trading at $0.07, up 2.94%, on heavy volume of approximately 15 million shares. Through yesterday’s close, NVLX average daily volume over the last 3 months has been 1 million shares. At current levels, Nuvilex commands a $24.4 million market cap.